Commercialization of Stem Cell Therapeutic Research: Bridging a Big Gap

Muhammad Irfan-maqsood, Monireh Bahrami, Mahdi Mirahmadi, Hojjat Naderi-meshkin

Muhammad Irfan-maqsood
Jinnah Stem Cell Institute (JSCI)

Monireh Bahrami
Ferdowsi University of Mashhad

Mahdi Mirahmadi
ACECR-Mashhad Branch

Hojjat Naderi-meshkin
ACECR-Mashhad Branch. Email: hojjat_naderi@yahoo.com
Online First: April 01, 2015 | Cite this Article
Irfan-maqsood, M., Bahrami, M., Mirahmadi, M., Naderi-meshkin, H. 2015. Commercialization of Stem Cell Therapeutic Research: Bridging a Big Gap. Journal of Genes and Cells 1(1-2): 40-45. DOI:10.15562/gnc.13

Stem cell therapeutic research is passing through a transition phase between laboratory research and health industry. According to the US data registry of clinical trials, more than 4776 studies have been registered, 2882 have been completed whereas 1894 studies are in process. Surprisingly, in spite of having huge research, there are two commercialized stem cell therapeutic products in global market and these two products are also not approved by FDA. As it has been discussed in literature, stem cells have been considered as promising candidates to treat non-curable diseases like cancer etc. More than 80% successful clinical trials have been done showing no or little side effects with much better efficiency than pharmacokinetics but still stem cell research is far from being commercialized. The major reason of stem cells non-commercialization is the gap among clinicians, researchers, industry experts and policy makers. A multibillion dollar grants and a very strong communication system between doctors, researchers, industrial experts, policy makers, regulating authorities, are the pre-requisite to commercialize stem cell therapy.

No Supplementary Material available for this article.
Article Views      : 1824
PDF Downloads : 595